Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 0.60 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | USP1 | O94782 | 4/20 | 0.34 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.33 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.33 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30212204 | 0.84 | NOTUM (0.54) | NOTUMEGLN1EGLN2CYP19A1TET2 | |
| SCHEMBL30046228 | 0.77 | NOTUM (0.56) | NOTUMEGLN1EGLN2CYP19A1CHRM1 | |
| SCHEMBL5612789 | 0.77 | NOTUM (0.56) | NOTUMEGLN1EGLN2CYP19A1CHRM1 | |
| SCHEMBL27950995 | 0.77 | NOTUM (0.39) | NOTUMEGLN1EGLN2CHRM1TET2 | |
| SCHEMBL12680212 | 0.77 | LMNA (0.53) | EGLN1USP1 | |
| SCHEMBL15114557 | 0.77 | NOTUM (0.60) | NOTUMEGLN1 | |
| SCHEMBL10130915 | 0.76 | CHRM1 (0.43) | NOTUMEGLN1EGLN2CYP19A1CHRM1 | |
| SCHEMBL12794021 | 0.75 | NOTUM (1.00) | NOTUMCYP19A1USP1 | |
| SCHEMBL12248368 | 0.75 | NOTUM (0.45) | NOTUMEGLN2CYP19A1 | |
| SCHEMBL1556693 | 0.74 | NOTUM (0.39) | NOTUMEGLN2CYP19A1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703757-B2 | Compounds and methods for CDK8 modulation and indications therefor | PLEXXIKON INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20180215763-A1 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215763-A1 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703757-B2 | Compounds and methods for CDK8 modulation and indications therefor | CDK8, CDK7, CDK18 | NOTUM 1387/4885EGLN1 3328/4885EGLN2 2588/4885 |
| US-20180215763-A1 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | CDK8, CDK7, CDK18 | NOTUM 1387/4885EGLN1 3328/4885EGLN2 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.